Navidea Biopharmaceuticals, Inc. (NAVB) announced the publication of results from two Phase 3 clinical trials of Lymphoseek Injection in patients with breast cancer. The trials assessed the performance of Lymphoseek against the standard of care, vital blue dye, in lymphatic mapping. Lymphoseek met its primary efficacy endpoint of rate of agreement, or concordance, with vital blue dye.
Lymphoseek is a receptor-targeted radiopharmaceutical recently approved by the U.S. FDA and indicated for use in lymphatic mapping for breast cancer and melanoma. In this procedure key lymph nodes adjacent to a primary tumor, that may contain tumor metastases, are identified and biopsied to determine if cancer has spread to these lymph nodes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.